Form 8-K - Current report:
SEC Accession No. 0001178913-25-000857
Filing Date
2025-03-17
Accepted
2025-03-17 08:00:22
Documents
18
Period of Report
2025-03-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zk2532871.htm   iXBRL 8-K 45775
2 EXHIBIT 10.1 exhibit_10-1.htm EX-10.1 467776
3 EXHIBIT 99.1 exhibit_99-1.htm EX-99.1 18596
8 image0.jpg GRAPHIC 36865
9 image1.jpg GRAPHIC 14847
  Complete submission text file 0001178913-25-000857.txt   877497

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA entx-20250316.xsd EX-101.SCH 4793
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE entx-20250316_def.xml EX-101.DEF 17919
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE entx-20250316_lab.xml EX-101.LAB 27305
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE entx-20250316_pre.xml EX-101.PRE 20104
21 EXTRACTED XBRL INSTANCE DOCUMENT zk2532871_htm.xml XML 6720
Mailing Address KIRYAT HADASSAH, MINRAV BUILDING FIFTH FLOOR JERUSALEM L3 9112002
Business Address KIRYAT HADASSAH, MINRAV BUILDING FIFTH FLOOR JERUSALEM L3 9112002 972-2-532-7151
Entera Bio Ltd. (Filer) CIK: 0001638097 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38556 | Film No.: 25742402
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)